Novozymes Biopharma (CSE: NZYMB) and Millipore Corporation (NYSE:MIL) launched the first product from their alliance to supply animal-free cell culture supplements for bioprocessing. CellPrime rTransferrin AF is the first animal-free alternative to serum-derived human or bovine transferrin for industrial cell culture and upstream biopharmaceutical applications.
CellPrime is a range of animal-free cell culture supplements that enable customers to utilize defined, animal-free supplements in their biopharmaceutical production processes. The new rTransferrin AF offers superior benefits over current plasma-derived alternatives, including facilitating effective iron uptake into cells for optimal cell culture and is now commercially available in scalable manufacturing quantities.
"We are pleased with the launch of our first commercial product and with the tremendous progress we have made in the first year of the alliance," said Caspar Foghsgaard, Senior Manager, Novozymes Biopharma. "Both Novozymes and Millipore share a vision for providing biopharmaceutical manufacturers with a broad range animal-free supplements for industrial cell culture applications. The launch of animal-free transferrin for industrial scale production represents the first step toward that shared vision."
CellPrime rTransferrin AF is designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers. It also improves the consistency of batch quality and productivity of customers' industrial cell culture processes. Manufactured in FDA-inspected facilities to cGMP standards, CellPrime rTransferrin AF is suitable for both research and commercial scale mammalian cell culture. Samples of the animal-free supplement are available from Millipore.
"The expansion of our animal-free cell culture supplements offering is a critical part of our Bioprocess Division's long-term strategy," said Andrew Bulpin, Vice President of Millipore's Upstream Bioprocessing Business Unit. "By working with an industry leader like Novozymes, we can complement our applications expertise to bring new, innovative products to the market that improve productivity and reduce the risk to our customers."
Building on Millipore Corporation's and Novozymes Biopharma's strong positions in the biopharmaceutical market, this new product will be manufactured by Novozymes Biopharma and sold exclusively through Millipore's sales organisation. The strength and expertise of both alliance partners assures the reliable long-term supply of these regulatory compliant supplements.
CellPrime is a trademark of Novozymes Biopharma and Millipore Corporation. Millipore is a registered trademark of Millipore Corporation. The M mark is a trademark of Millipore Coporation. Novozymes Biopharma is a wholly owned subsidiary of Novozymes A/S, Kroshojvej 36, 2880 Bagsværd, Denmark.
Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.
Novozymes' natural solutions enhance and promote everything from removing trans-fats in food, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature's potential is evidenced by over 4,500 patents, showing what is possible when nature and technology join forces.
Our 4,500+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.
Millipore (millipore.com) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, the company collaborates with customers to confront the world's challenging human health issues.
From research to development to production, Millipore's scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with 6,000 employees in 47 countries worldwide.
Millipore Forward Looking Statement
The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.
Potential risks and uncertainties that could affect Millipore's future operating results with respect to the foregoing include, without limitation, failure to achieve market penetration or to develop additional products acceptable to the cell culture market, failure to achieve design wins into our pharmaceutical and biotechnology customers' manufacturing design phase for a particular drug; delay, suspension or termination of a customer's volume production; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to increased debt service obligations; the inability to establish and maintain necessary product and process quality levels; the inability to realize the expected benefits of the Novozymes development, marketing and licensing alliance; competitive factors such as alternative cell culture supplements; the inability to utilize technology in current or planned products due to overriding rights by third parties; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; and exposure to product liability claims. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.